company background image
SERA

Sera Prognostics NasdaqGM:SERA Stock Report

Last Price

US$1.40

Market Cap

US$43.4m

7D

-8.5%

1Y

-80.1%

Updated

04 Feb, 2023

Data

Company Financials +

Sera Prognostics, Inc.

NasdaqGM:SERA Stock Report

Mkt Cap: US$43.4m

SERA Stock Overview

Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes.

SERA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Sera Prognostics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sera Prognostics
Historical stock prices
Current Share PriceUS$1.40
52 Week HighUS$7.29
52 Week LowUS$1.10
Beta0
1 Month Change1.45%
3 Month Change3.70%
1 Year Change-80.11%
3 Year Changen/a
5 Year Changen/a
Change since IPO-88.24%

Recent News & Updates

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Nov 03
We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Recent updates

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Nov 03
We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Aug 10

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Jul 21
We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Shareholder Returns

SERAUS BiotechsUS Market
7D-8.5%-0.8%1.7%
1Y-80.1%4.4%-9.6%

Return vs Industry: SERA underperformed the US Biotechs industry which returned 4.4% over the past year.

Return vs Market: SERA underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is SERA's price volatile compared to industry and market?
SERA volatility
SERA Average Weekly Movement13.6%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: SERA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: SERA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008114Greg Critchfieldhttps://seraprognostics.com

Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.

Sera Prognostics, Inc. Fundamentals Summary

How do Sera Prognostics's earnings and revenue compare to its market cap?
SERA fundamental statistics
Market CapUS$43.42m
Earnings (TTM)-US$46.92m
Revenue (TTM)US$229.00k

189.6x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SERA income statement (TTM)
RevenueUS$229.00k
Cost of RevenueUS$148.00k
Gross ProfitUS$81.00k
Other ExpensesUS$47.01m
Earnings-US$46.92m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.51
Gross Margin35.37%
Net Profit Margin-20,490.83%
Debt/Equity Ratio0%

How did SERA perform over the long term?

See historical performance and comparison